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KEY MESSAGES
 Over one in five patients with T2DM in general practice had a current prescription for antidepressants or
benzodiazepines
 These patients have higher primary and secondary healthcare utilization
 There is no difference in rates of glycaemic control for patients with or without a current prescription for
an antidepressant or a benzodiazepine
ABSTRACT
Background: Comorbid anxiety and depression and type two diabetes mellitus (T2DM) are com-
monly managed by General Practitioners (GPs).
Objectives: To investigate the proportion of people with T2DM who are prescribed either anti-
depressant or benzodiazepine medications in general practice; to compare people with T2DM
that have a prescription with those that do not in terms of patient characteristics, glycaemic
control and healthcare utilization.
Methods: Anonymized data was collected by GPs and senior medical students from electronic
medical records of patients with T2DM in 34 Irish general practices affiliated with the University
of Limerick Graduate Entry Medical School during the 2013/14 academic year. Data included
demographics, healthcare utilization, prescriptions and most recent glycosylated haemoglobin
(HbA1c) measurement.
Results: The sample included 2696 patients with T2DM, of which 733 (36.7%) were female, and
with a median age of 66 years. The percentage with a current prescription for an antidepressant
or benzodiazepine was 22% (95%CI: 18.9–24.9). Those with a current prescription for either drug
were more likely to have attended the emergency department (28.3% vs 15.7%, P<0.001), to
have been admitted to hospital (35.4% vs 21.3%, P<0.001) in the past year and attend their GP
more frequently (median of 9 vs 7, P<0.001) than those without a prescription. Rates of poor
glycaemic control were similar in those with and without a current prescription.
Conclusion: Over one-fifth of people with T2DM in Irish general practice are prescribed an anti-
depressant or benzodiazepine medication. Prescription of these is associated with increased
healthcare utilization but not poorer glycaemic control.
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Introduction
Depression and anxiety frequently co-exist in the gen-
eral population and commonly occur in people with
diabetes mellitus with the presence of one increasing
the risk of developing the other [1,2]. Furthermore, the
comorbid state is associated with poorer outcomes for
each condition [3]. Depression occurring in the type
two diabetes mellitus (T2DM) population tends to have
a particularly strong anxiety component [4]. General
practitioners (GPs) are responsible for diagnosing and
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treating most people with T2DM and comorbid depres-
sion and anxiety, frequently prescribing benzodiazepine
and antidepressant medications [5,6]. As well as their
use in the management of depression and anxiety [7],
these medications are commonly prescribed to people
with untreated and undiagnosed depression [8]. Both
classes of medication are associated with significant
physical health risks [9,10].
Depression in T2DM has a point prevalence of
10–15% but there is no data on the proportion of
people with T2DM that are prescribed an antidepres-
sant or a benzodiazepine medication [11]. When either
depression or anxiety, or both, are present in people
with diabetes, the risk of mortality increases [12]. The
reasons for this are unclear but it is an important clin-
ical point for GPs who manage these conditions daily.
Similarly, the effect of comorbid depression and anx-
iety on glycaemic control remains uncertain [13].
Screening for depression and anxiety is not routinely
recommended in the general practice care of people
with T2DM, but knowing the patient characteristics
that are associated with these conditions may help
GPs in their management. Furthermore, research on a
range of chronic illness reported that comorbid
depression and anxiety symptoms were associated
with twice the likelihood of health service use [14].
There is no available data on the effect of these symp-
toms on the health service use of people with T2DM
in general practice. With GPs expected to coordinate
secondary care referrals and appropriate use of service
resources, knowledge on healthcare utilization among
this population is important for health planning [15].
The objectives of this study, therefore, were first, to
establish what proportion of people with T2DM were
prescribed benzodiazepine or antidepressant medica-
tions, and second, to investigate the difference in
patients prescribed these medications to those who
were not with regard to:
1. Practice and patient characteristics
2. Glycaemic control, using glycosylated haemoglo-
bin (HbA1c)
3. Health service utilization (of primary and second-
ary healthcare services)
Methods
Study design
This was an observational study involving a retrospect-
ive analysis of patient records. It is part of a larger
study on the management of patients with T2DM in
general practice [16].
Ethics
The Mid-Western Regional Hospital Research Ethics
Committee granted ethical approval for the study (22
May 2013).
Study setting
All 51 practices affiliated with the University of
Limerick Graduate Entry Medical School, located in the
mid-west of Ireland, with a senior medical student on
placement in 2013/14 were invited to participate in
this study. These practices are based in three of
Ireland’s four healthcare regions, which serve a popu-
lation of 3.5 million. Ireland has a mixed public/private
healthcare system, with approximately 43% of the
population eligible for free healthcare [17]. At the
time of data collection, there was no structured deliv-
ery of care nationally to patients with T2DM in primary
care in Ireland.
Study sample
Senior medical students on placement and their GP
supervisors used existing diabetes registers or report-
ing functions of electronic practice management sys-
tems to generate a list of all patients with T2DM in
the practice. Where no register existed, patients were
identified using disease coding, medications or the
recording of the use of blood glucose monitors in the
practice management system. The practice team
reviewed all lists to ensure they were up to date and
complete. For feasibility of detailed data extraction
and to ensure comparable workload for students on
placement across practices, in practices with over 100
patients with T2DM, a random sample of 100 patients
was selected using the random number function in
Microsoft Excel.
Measurements
A standardized data extraction tool was used to record
the following information for those patients with
T2DM who had consulted with their GP in the previ-
ous year (1 September 2012 to 31 August 2013):
 Age
 Gender
 Eligibility for free healthcare
 Current prescription for antidepressants or
benzodiazepine
 Smoking status: current smoker, non-smoker or
smoking status not recorded in the previous year
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 Body mass index (BMI): BMI <25 kg/m2; BMI of
25–30 kg/m2; BMI  30 kg/m2 or BMI not recorded
in the previous year
 Healthcare utilization in the previous year: total
number of GP consultations where a consultation
is defined as any visit or telephone conversation
that resulted in an entry to patient records; any
attendance to the emergency department; any hos-
pital admission; any referral or attendance to spe-
cialist mental health services; any referral or
attendance to an endocrinologist
 most recent measurement of HbA1c in mmol/mol.
Poor glycaemic control was defined as HBA1c
greater than 8% (64mmol/mol)
 whether the practice was in an urban (concen-
trated geographical area with 5000 or more resi-
dents), rural (scattered population over a large
geographical area) or mixed urban/rural location
(both concentrated and scattered population) [18]
 a classification of the deprivation of the area in
which the practice was located based on the All-
Ireland HP Deprivation Index [19]
 the number of full-time GPs in the practice
 the number of part-time and full-time prac-
tice nurses
 whether the practice was a member of a primary
care team
Data were entered using the standardized data
template in each practice and anonymized data sets
from all practices were merged into a master file.
Statistical analyses
The proportion of patients with a current prescription
for antidepressants or benzodiazepines was estimated
with a 95%CI for the proportion, using the SAS pro-
cedure SURVEYFREQ to account for clustering of
patients within practices. Demographic and healthcare
utilization variables were summarized using graphical
and numeric descriptive statistics. Medians were com-
pared across groups (those with a current prescription,
those without) using non-parametric tests and
Pearson’s chi-squared test was used to investigate
associations between categorical variables. A multiple
logistic regression analysis was carried out to measure
associations between current antidepressant or benzo-
diazepine prescription (yes/no) using both patient
level characteristics and practice level characteristics
as explanatory variables. A 5% level of significance
was used for all tests and odds ratios with 95%CIs
are reported.
Results
Practices
Out of the 51 practices were invited to participate in
this study and a total of 34 practices participated
(67% of eligible practices). Practice size ranged from
1169–22 352 patients with a median of 5160 patients.
Most (79%) of participating practices had an existing
diabetes register. All patients with T2DM were
included from half of the participating practices with
the numbers of less than 100, and, in the remaining
half of practices, a random sample of 100 patients
with T2DM was selected. Table 1 outlines the charac-
teristics of participating practices (n= 34 practices).
Patients with and without a prescription for a
psychotropic drug
The final sample was 2696 patients with T2DM who
had visited their GP in the previous year. The median
age of the sample was 67 years (range: 11–100 years)
and the majority of the sample were male (61%) and
eligible for free healthcare (77%). The percentage of
patients with T2DM with a current prescription for an
antidepressant or benzodiazepine was 22%
(95%CI: 18.9–24.9).
Table 2 compares the characteristics and healthcare
utilization of patients with and without a current pre-
scription. Those with a current prescription for antide-
pressants or benzodiazepine were more likely to be
female, eligible for free healthcare and be recorded as
a current smoker compared to those without a current
prescription (Table 2). Those with a current prescrip-
tion were more likely to have attended the emergency
department, be admitted to hospital, have been
referred to or attended specialist mental health
Table 1. Characteristics of participating practices
(n¼ 34 practices).
Practice characteristics Practices n (%)
Number of full-time GPs
One/two 17 (50)
Three/four 17 (50)
Practice nurse
Full-time 20 (58.8)
Part-time 14 (41.2)
Location
Urban 8 (23.5)
Rural 14 (41.2)
Mixed urban/rural 12 (35.3)
Member of a primary care team 11 (32.4)
Deprivation index
Disadvantaged 10 (29.4)
Marginally below average 13 (38.2)
Marginally above average 8 (23.5)
Affluent 3 (8.8)
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services in the past year and consult with their GP
more frequently compared to those without a current
prescription (Table 2). There were no differences in
age, BMI or the rates of referral/attendance to an
endocrinologist between the two groups.
The relationship between glycaemic control and
psychotropic drug use
A recent measurement (within the previous 12
months) of HbA1c was available for 88% of the
patients (n¼ 2362). The distributions of the most
recent measurement of HbA1c were similar for both
groups (Table 2).
Using a cut-off of greater than 8% (64mmol/mol)
to represent poor glycaemic control, a similar propor-
tion (of approximately 18.3%) in both groups were
above the cut-off point.
Factors associated with prescription of
psychotropic drugs
A multiple logistic regression analysis to measure asso-
ciations between practice and patient characteristics
with having a current prescription for antidepressants
or benzodiazepines identified that female gender,
being eligible for free healthcare, being a current
smoker and consulting with the GP more frequently
were independently associated with statistically signifi-
cant increased odds of having a current prescription
(Table 3). An urban location for the practice was also
associated with statistically significant increased odds
of having a current prescription (Table 3).
Discussion
Main findings
This study, conducted in 34 practices in Ireland,
including 2696 patients with T2DM who had visited
Table 3. Multiple logistic regression of current antidepressant
or benzodiazepine prescription (yes, no) in patients with type
two diabetes mellitus (n¼ 2,696)
Explanatory variablea Odds ratio (95%CI) P-value
Patient characteristics
Gender
Female gender (male ¼ 1) 1.43 (1.16–1.78) 0.0009
Eligible for free healthcare (no ¼ 1) 2.17 (1.62–2.90) <0.0001
Number of GP consultations 1.04 (1.02–1.05) <0.0001
Smoking status (non-smoker ¼ 1)
Smoker 1.74 (1.26–2.40) 0.0014
Unknown 1.24 (0.92–1.67) 0.64
Practice characteristics
Practice location (mixed ¼ 1)
Urban 1.55 (1.11–2.16) 0.0005
Rural 0.86 (0.56–1.32) 0.052
aFinal model presented with all variables statistically significant (P<0.05).
Table 2. Characteristics and healthcare utilization of patients with type two diabetes mellitus, with or without a current prescrip-
tion for antidepressants or benzodiazepine.
Patients without a
current prescription
(n¼ 2106)
Patients with
a current
prescription
(n¼ 590) P-value
Age
Median (range) 66 years
(11–100 years)
67 years
(27–96 years)
0.22
Female gender 733 (36.7%) 287 (48.6%) <0.001
Eligible for free healthcare 1566 (74.5%) 519 (88.1%) <0.001
Current smoking status
Unknown 1015 (48.2%) 286 (48.5%) <0.001
Non-smoker 868 (41.2%) 209 (35.4%)
Current smoker 223 (10.6%) 95 (16.1%)
Body mass index (BMI)
BMI not recorded 1056 (50.2%) 305 (51.7%) 0.13
BMI <25 kg/m2 129 (6.1%) 31 (5.3%)
BMI 25–30 kg/m2 386 (18.3%) 87 (14.7%)
BMI  30 kg/m2 535 (25.4%) 167 (28.3%)
HbA1c
Median 6.8% (51mmol/mol) 6.8% (51mol/mol)
First to third quartile 6.3–7.6% 6.3–7.7%
Exceeds cut-off point of 8% (64mmol/ mol) 18.2% 18.9% 0.71
Number of GP consultations
Median 7 9 <0.001
First to third quartile 3–12 5–16
Secondary healthcare utilization
Attendance at the emergency department 331 (15.7%) 167 (28.3%) <0.001
Referral/attendance to endocrinologist 447 (21.2%) 110 (18.6%) 0.17
Referral/attendance to specialist mental health services 24 (1.1%) 128 (21.7%) <0.001
Hospital admission 448 (21.3%) 209 (35.4%) <0.001
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their GP in the previous year, found 22% of these
patients had a prescription for an antidepressant or
benzodiazepine. Those with a current prescription
were more likely to have attended the emergency
department, be admitted to hospital, have attended
specialist mental health services in the past year or
have attended the GP more frequently compared to
those without a prescription. There was no significant
difference between rates of glycaemic control for
those with or without a current prescription for anti-
depressants or benzodiazepines. In a multivariable
model, we identified five independent factors associ-
ated with the prescription of a psychotropic drug in
this population: female gender, frequent attendance
to the GP, tobacco smoking, attendance at urban
centres and eligibility for free healthcare.
Prevalence of psychotropic drug prescription
The figure of 22% of the T2DM population in this
study prescribed these drugs may be explained by
previous findings that up to 20% of people with any
type of diabetes mellitus have a major depressive dis-
order [20].
A recent study of benzodiazepine prescribing
showed that the rate of prescribing has been
decreasing in Ireland [21]. The paper reported that in
2015 the rate of prescribing of benzodiazepines in
the general population was 16.6% [21]. Similarly, anti-
depressant prescribing rates vary between countries,
from 3% in Dutch centres to 9% in UK centres [22].
The most recent available analysis in Ireland reports
an antidepressant prescribing rate of 5% [23]. In
broad terms, the combined prescribing rates in the
general population do not appear to be dissimilar to
the prescribing rate of people with T2DM reported in
this study. However, a crude combination would
likely overestimate the actual numbers prescribed
these medications as it would twice include the sig-
nificant number of people likely be prescribed
both drugs.
Psychotropic drugs and glycaemic control
Our finding that glycaemic control, as measured by
HBA1c, is not significantly associated with antidepres-
sant or benzodiazepine use, contributes new informa-
tion to an important clinical question. The relationship
between mood and glycaemic control is unclear, with
one study finding that depressive symptoms were not
associated with poor glycaemic control in T2DM [24],
while another study showed a sustained improvement
in mood was associated with improved glycaemic con-
trol in T2DM [25]. In this study, a less stringent cut-off
point was applied because of the presence of older
age profile and presence of comorbidities [26]. This
may lead to a comparatively lower proportion of peo-
ple with ‘poor’ glycaemic control.
Psychotropic drugs and healthcare utilization
While people that are prescribed antidepressants or
benzodiazepines had similar glycaemic control to
those that did not, they were more likely to attend
the GP as well as secondary care services. The fact
that an underlying psychological condition is expected
to be present may explain the higher attendance to
specialist mental health services, but the study also
found higher attendances at the emergency depart-
ment as well as being more likely to be admitted to
hospital. Interestingly, the rates of attendance at spe-
cialist endocrinology services were similar, suggesting
that there may not necessarily be a higher rate of dia-
betes-related complications among people prescribed
these medications. The presence of comorbid major
depression in any physical condition is linked to
approximately double the likelihood of healthcare util-
ization [14]. High-risk health behaviour, including
smoking, and increased incidence of adverse heart
events have been reported in people with depression
in T2DM [27] and this may account for the increased
use of emergency departments and inpatient admis-
sions. The increased secondary care utilization has
health service planning implications as management
of T2DM in primary care is much more cost-effective
[28] and people with the condition who are managed
in primary care have better indices of quality of life
with similar health outcomes compared to secondary
care [29].
Factors associated with prescription of psychotropic
drugs
The association we found with female gender could
be explained by research showing that women with a
physical illness were more likely to access mental
health services than men and that for women more
than men with depressive symptoms [30], the risk of
developing T2DM is higher [31]. The association with
higher GP attendance rates is similar to findings
reported by Brieler et al., and is possibly because the
high prevalence of anxiety-related symptoms may
increase these patients’ attendance rates [25,32]. We
found no higher prescribing prevalence in people with
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T2DM in areas of social deprivation but prevalence
was higher in people who were eligible for unre-
stricted public medical care (mostly lower income)
similar to Jacob et al. [33]. The association with smok-
ing and having a prescription for a psychotropic medi-
cation is consistent with previous research showing
increased rates of smoking in people that are pre-
scribed this medication [34].
Strengths and limitations
The strengths of this study include the large sample
size of clinical records of patients reviewed across a
large number of practices and the scope of the exam-
ination of clinical records. The practices that partici-
pated are considered a representative sample of all
practices by size, urban/rural location and patient eli-
gibility for free care.
Study limitations include that we only can say that
benzodiazepine or antidepressant drugs were or were
not prescribed. We have used prescribing as a proxy
for mental illness while acknowledging that a minority
of prescriptions for these medications may be used for
the treatment of neuropathic pain or sleep disorders.
The observational design of this study limits the
strength of the conclusions we can draw about the
differences between those with a current prescription
or not. We also have not compared our results on
patients with T2DM to patients without T2DM who are
currently prescribed antidepressants or benzodiaze-
pines. No exact dates of measurement for HbA1c were
collected but all measurements were taken within the
previous 12 months. Lastly, objective glucose measure-
ments, with which to make comparisons, were
not available.
Further research
The authors recommend that future research should
focus on the reasons for increased secondary health-
care use in patients with a current prescription and
the appropriateness of this use, particularly of the
emergency department.
Conclusion
This study highlights that, among a T2DM general
practice population, over one in five are prescribed
antidepressant and benzodiazepine medication.
Having a prescription for these medications is associ-
ated with increased secondary healthcare use, in par-
ticular attendance at emergency departments and
hospital admission, which has serious implications for
individual health, quality of life and health ser-
vice planning.
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